View ValuationDaesung Microbiological Labs 将来の成長Future 基準チェック /06現在、 Daesung Microbiological Labsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長21.9%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Mar 25Insilico Co. Ltd. completed the acquisition of 38.60% stake in Daesung Microbiological Labs. Co., Ltd. (KOSDAQ:A036480) from Lee Dong-gyu and Lee Hoon-gu.Insilico Co. Ltd. entered into a stock transfer agreement to acquire 38.60% stake in Daesung Microbiological Labs. Co., Ltd. (KOSDAQ:A036480) from Lee Dong-gyu and Lee Hoon-gu for KRW 16.1 billion on March 9, 2026. A cash consideration of KRW 16.13 billion will be paid by Insilico Co. Ltd. As part of consideration, KRW 16.13 billion is paid towards common equity of Daesung Microbiological Labs. Co., Ltd. The expected completion of the transaction is March 31, 2026. Insilico Co. Ltd. completed the acquisition of 38.60% stake in Daesung Microbiological Labs. Co., Ltd. (KOSDAQ:A036480) from Lee Dong-gyu and Lee Hoon-gu on March 24, 2026. The transaction was funded through equity funds of KRW 2.63 billion and borrowings of KRW 13.5 billion.Valuation Update With 7 Day Price Move • Mar 10Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩8,120, the stock trades at a trailing P/E ratio of 23x. Average trailing P/E is 22x in the Biotechs industry in South Korea. Total loss to shareholders of 17% over the past three years.お知らせ • Feb 12Daesung Microbiological Labs. Co., Ltd., Annual General Meeting, Mar 24, 2026Daesung Microbiological Labs. Co., Ltd., Annual General Meeting, Mar 24, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 103, deogyeong-daero, gyeonggi-do, uiwang South KoreaUpcoming Dividend • Dec 22Upcoming dividend of ₩75.00 per shareEligible shareholders must have bought the stock before 29 December 2025. Payment date: 27 April 2026. Trailing yield: 1.0%. Lower than top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (0.6%).Reported Earnings • Nov 12Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: ₩7.18b (up 24% from 3Q 2024). Net income: ₩752.6m (up ₩2.08b from 3Q 2024). Profit margin: 11% (up from net loss in 3Q 2024). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 86 percentage points per year, which is a significant difference in performance.Declared Dividend • Nov 08Dividend of ₩75.00 announcedDividend of ₩75.00 is the same as last year. Ex-date: 29th December 2025 Payment date: 27th April 2026 Dividend yield will be 1.1%, which is higher than the industry average of 0.5%. Sustainability & Growth The dividend has not increased over the past 4 years but payments have been stable during that time.お知らせ • Nov 07Daesung Microbiological Labs. Co., Ltd. announces Annual dividend, payable on April 27, 2026Daesung Microbiological Labs. Co., Ltd. announced Annual dividend of KRW 75.0000 per share payable on April 27, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.お知らせ • Feb 26Daesung Microbiological Labs. Co., Ltd., Annual General Meeting, Mar 26, 2025Daesung Microbiological Labs. Co., Ltd., Annual General Meeting, Mar 26, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 103, deogyeong-daero, gyeonggi-do, uiwang South KoreaUpcoming Dividend • Dec 20Upcoming dividend of ₩75.00 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 23 April 2025. The company last paid an ordinary dividend in April 2022. The average dividend yield among industry peers is 0.5%.New Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩36.2b market cap, or US$25.2m).Declared Dividend • Nov 14Dividend of ₩75.00 announcedShareholders will receive a dividend of ₩75.00. Ex-date: 27th December 2024 Payment date: 23rd April 2025 Dividend yield will be 0.8%, which is higher than the industry average of 0.5%.分析記事 • Aug 06Daesung Microbiological Labs (KOSDAQ:036480) Is Carrying A Fair Bit Of DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Upcoming Dividend • Dec 20Upcoming dividend of ₩75.00 per share at 0.7% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 19 April 2024. Trailing yield: 0.7%. Lower than top quartile of South Korean dividend payers (3.5%). In line with average of industry peers (0.7%).New Risk • Oct 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 23% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Profit margins are more than 30% lower than last year (1.8% net profit margin). Market cap is less than US$100m (₩55.2b market cap, or US$40.8m).Reported Earnings • May 18First quarter 2023 earnings released: EPS: ₩40.00 (vs ₩454 in 1Q 2022)First quarter 2023 results: EPS: ₩40.00 (down from ₩454 in 1Q 2022). Revenue: ₩5.73b (down 9.9% from 1Q 2022). Net income: ₩152.2m (down 91% from 1Q 2022). Profit margin: 2.7% (down from 27% in 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.Valuation Update With 7 Day Price Move • May 11Investor sentiment improves as stock rises 30%After last week's 30% share price gain to ₩12,790, the stock trades at a trailing P/E ratio of 28.5x. Average trailing P/E is 25x in the Biotechs industry in South Korea. Total loss to shareholders of 7.6% over the past three years.Upcoming Dividend • Dec 21Upcoming dividend of ₩75.00 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 19 April 2023. Trailing yield: 0.7%. Lower than top quartile of South Korean dividend payers (3.3%). In line with average of industry peers (0.7%).Valuation Update With 7 Day Price Move • Sep 28Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩10,000, the stock trades at a trailing P/E ratio of 17.5x. Average trailing P/E is 21x in the Biotechs industry in South Korea. Total loss to shareholders of 44% over the past three years.Valuation Update With 7 Day Price Move • Jun 20Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₩11,850, the stock trades at a trailing P/E ratio of 17.5x. Average trailing P/E is 23x in the Biotechs industry in South Korea. Total loss to shareholders of 36% over the past three years.Reported Earnings • May 18First quarter 2022 earnings released: EPS: ₩454 (vs ₩6.00 in 1Q 2021)First quarter 2022 results: EPS: ₩454 (up from ₩6.00 in 1Q 2021). Revenue: ₩6.36b (up 14% from 1Q 2021). Net income: ₩1.73b (up ₩1.70b from 1Q 2021). Profit margin: 27% (up from 0.5% in 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.Upcoming Dividend • Dec 22Inaugural dividend of ₩85.00 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 18 April 2022. The company is not currently making a profit and is not cash flow positive. This is the first dividend for Daesung Microbiological Labs since going public. The average dividend yield among industry peers is 0.8%.Reported Earnings • May 19First quarter 2021 earnings released: EPS ₩6.00 (vs ₩204 in 1Q 2020)The company reported a poor first quarter result with weaker earnings, revenues and profit margins. First quarter 2021 results: Revenue: ₩5.60b (down 18% from 1Q 2020). Net income: ₩25.7m (down 97% from 1Q 2020). Profit margin: 0.5% (down from 12% in 1Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.分析記事 • May 08Is Daesung Microbiological Labs (KOSDAQ:036480) Using Too Much Debt?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Mar 15Is The Market Rewarding Daesung Microbiological Labs. Co., Ltd. (KOSDAQ:036480) With A Negative Sentiment As A Result Of Its Mixed Fundamentals?Daesung Microbiological Labs (KOSDAQ:036480) has had a rough month with its share price down 9.5%. We, however decided...お知らせ • Feb 25Daesung Microbiological Labs. Co., Ltd., Annual General Meeting, Mar 26, 2021Daesung Microbiological Labs. Co., Ltd., Annual General Meeting, Mar 26, 2021, at 09:00 Korea Standard Time.分析記事 • Feb 17We're Not Counting On Daesung Microbiological Labs (KOSDAQ:036480) To Sustain Its Statutory ProfitabilityIt might be old fashioned, but we really like to invest in companies that make a profit, each and every year. That...分析記事 • Jan 21Is Daesung Microbiological Labs (KOSDAQ:036480) A Risky Investment?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Valuation Update With 7 Day Price Move • Jan 19Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₩21,600, the stock is trading at a trailing P/E ratio of 33.7x, up from the previous P/E ratio of 28.3x. This compares to an average P/E of 62x in the Biotechs industry in South Korea. Total returns to shareholders over the past three years are 102%.Valuation Update With 7 Day Price Move • Jan 13Investor sentiment improved over the past weekAfter last week's 30% share price gain to ₩21,700, the stock is trading at a trailing P/E ratio of 33.8x, up from the previous P/E ratio of 26x. This compares to an average P/E of 57x in the Biotechs industry in South Korea. Total returns to shareholders over the past three years are 111%.Valuation Update With 7 Day Price Move • Jan 11Investor sentiment improved over the past weekAfter last week's 26% share price gain to ₩20,600, the stock is trading at a trailing P/E ratio of 32.1x, up from the previous P/E ratio of 25.5x. This compares to an average P/E of 58x in the Biotechs industry in South Korea. Total returns to shareholders over the past three years are 102%.Is New 90 Day High Low • Jan 11New 90-day high: ₩20,600The company is up 24% from its price of ₩16,600 on 13 October 2020. The South Korean market is up 29% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is up 20% over the same period.分析記事 • Dec 31Update: Daesung Microbiological Labs (KOSDAQ:036480) Stock Gained 83% In The Last Five YearsGenerally speaking the aim of active stock picking is to find companies that provide returns that are superior to the...Upcoming Dividend • Dec 22Upcoming Dividend of ₩85.00 Per ShareWill be paid on the 17th of April to those who are registered shareholders by the 29th of December. The company last paid an ordinary dividend in March 2010. The average dividend yield among industry peers is 0.3%.分析記事 • Dec 10Daesung Microbiological Labs. Co., Ltd. (KOSDAQ:036480) Is Up But Financials Look Inconsistent: Which Way Is The Stock Headed?Daesung Microbiological Labs' (KOSDAQ:036480) stock is up by 4.3% over the past month. However, the company's...分析記事 • Nov 19Here's Why We Don't Think Daesung Microbiological Labs's (KOSDAQ:036480) Statutory Earnings Reflect Its Underlying Earnings PotentialStatistically speaking, it is less risky to invest in profitable companies than in unprofitable ones. However... このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Daesung Microbiological Labs は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測KOSDAQ:A036480 - アナリストの将来予測と過去の財務データ ( )KRW Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/202625,8706541,4091,784N/A12/31/202525,9895981,0521,410N/A9/30/202525,8621,3431,2381,710N/A6/30/202524,494-7372,3032,784N/A3/31/202523,412-1,7191,6472,142N/A12/31/202423,804-1,7691,3072,103N/A9/30/202424,164-2,7994801,558N/A6/30/202424,009-2,602-1,116-136N/A3/31/202425,423-1,147-1,236-141N/A12/31/202325,562-680-2,494-1,234N/A9/30/202325,502-674-3,098-1,686N/A6/30/202324,796441-3,229-720N/A3/31/202324,871127-2,748-205N/A12/31/202225,5001,703-1,1601,155N/A9/30/202225,1672,493-4772,177N/A6/30/202225,6492,174-5421,694N/A3/31/202224,7602,568-7461,932N/A12/31/202123,997866-7662,203N/A9/30/202123,179-265-7,2411,918N/A6/30/202123,374335-8,4752,137N/A3/31/202123,616766-8,9093,580N/A12/31/202024,8011,519-11,2083,236N/A9/30/202025,4082,058-10,3961,920N/A6/30/202024,5151,882-9,4652,926N/A3/31/202025,8682,510-11,1872,876N/A12/31/201925,1342,471N/A2,315N/A9/30/201924,9183,566N/A4,441N/A6/30/201926,5444,255N/A3,410N/A3/31/201925,4833,622N/A2,897N/A12/31/201825,0973,170N/A3,136N/A9/30/201824,1592,098N/A2,739N/A6/30/201824,0881,654N/A3,896N/A3/31/201824,1511,686N/A2,330N/A12/31/201724,0431,558N/A1,681N/A9/30/201726,0222,611N/A1,548N/A6/30/201727,3533,089N/A1,862N/A3/31/201728,5493,475N/A2,197N/A12/31/201630,8014,495N/A3,521N/A9/30/201631,8054,583N/A5,731N/A6/30/201629,8684,167N/A5,525N/A3/31/201631,0864,213N/A6,346N/A12/31/201531,0264,550N/A7,663N/A9/30/201529,4293,786N/A4,967N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: A036480の予測収益成長が 貯蓄率 ( 3.1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: A036480の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: A036480の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: A036480の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: A036480の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: A036480の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/04 19:00終値2026/07/03 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Daesung Microbiological Labs. Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Mar 25Insilico Co. Ltd. completed the acquisition of 38.60% stake in Daesung Microbiological Labs. Co., Ltd. (KOSDAQ:A036480) from Lee Dong-gyu and Lee Hoon-gu.Insilico Co. Ltd. entered into a stock transfer agreement to acquire 38.60% stake in Daesung Microbiological Labs. Co., Ltd. (KOSDAQ:A036480) from Lee Dong-gyu and Lee Hoon-gu for KRW 16.1 billion on March 9, 2026. A cash consideration of KRW 16.13 billion will be paid by Insilico Co. Ltd. As part of consideration, KRW 16.13 billion is paid towards common equity of Daesung Microbiological Labs. Co., Ltd. The expected completion of the transaction is March 31, 2026. Insilico Co. Ltd. completed the acquisition of 38.60% stake in Daesung Microbiological Labs. Co., Ltd. (KOSDAQ:A036480) from Lee Dong-gyu and Lee Hoon-gu on March 24, 2026. The transaction was funded through equity funds of KRW 2.63 billion and borrowings of KRW 13.5 billion.
Valuation Update With 7 Day Price Move • Mar 10Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩8,120, the stock trades at a trailing P/E ratio of 23x. Average trailing P/E is 22x in the Biotechs industry in South Korea. Total loss to shareholders of 17% over the past three years.
お知らせ • Feb 12Daesung Microbiological Labs. Co., Ltd., Annual General Meeting, Mar 24, 2026Daesung Microbiological Labs. Co., Ltd., Annual General Meeting, Mar 24, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 103, deogyeong-daero, gyeonggi-do, uiwang South Korea
Upcoming Dividend • Dec 22Upcoming dividend of ₩75.00 per shareEligible shareholders must have bought the stock before 29 December 2025. Payment date: 27 April 2026. Trailing yield: 1.0%. Lower than top quartile of South Korean dividend payers (3.6%). Higher than average of industry peers (0.6%).
Reported Earnings • Nov 12Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: ₩7.18b (up 24% from 3Q 2024). Net income: ₩752.6m (up ₩2.08b from 3Q 2024). Profit margin: 11% (up from net loss in 3Q 2024). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 86 percentage points per year, which is a significant difference in performance.
Declared Dividend • Nov 08Dividend of ₩75.00 announcedDividend of ₩75.00 is the same as last year. Ex-date: 29th December 2025 Payment date: 27th April 2026 Dividend yield will be 1.1%, which is higher than the industry average of 0.5%. Sustainability & Growth The dividend has not increased over the past 4 years but payments have been stable during that time.
お知らせ • Nov 07Daesung Microbiological Labs. Co., Ltd. announces Annual dividend, payable on April 27, 2026Daesung Microbiological Labs. Co., Ltd. announced Annual dividend of KRW 75.0000 per share payable on April 27, 2026, ex-date on December 29, 2025 and record date on December 31, 2025.
お知らせ • Feb 26Daesung Microbiological Labs. Co., Ltd., Annual General Meeting, Mar 26, 2025Daesung Microbiological Labs. Co., Ltd., Annual General Meeting, Mar 26, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 103, deogyeong-daero, gyeonggi-do, uiwang South Korea
Upcoming Dividend • Dec 20Upcoming dividend of ₩75.00 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 23 April 2025. The company last paid an ordinary dividend in April 2022. The average dividend yield among industry peers is 0.5%.
New Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩36.2b market cap, or US$25.2m).
Declared Dividend • Nov 14Dividend of ₩75.00 announcedShareholders will receive a dividend of ₩75.00. Ex-date: 27th December 2024 Payment date: 23rd April 2025 Dividend yield will be 0.8%, which is higher than the industry average of 0.5%.
分析記事 • Aug 06Daesung Microbiological Labs (KOSDAQ:036480) Is Carrying A Fair Bit Of DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Upcoming Dividend • Dec 20Upcoming dividend of ₩75.00 per share at 0.7% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 19 April 2024. Trailing yield: 0.7%. Lower than top quartile of South Korean dividend payers (3.5%). In line with average of industry peers (0.7%).
New Risk • Oct 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 23% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Profit margins are more than 30% lower than last year (1.8% net profit margin). Market cap is less than US$100m (₩55.2b market cap, or US$40.8m).
Reported Earnings • May 18First quarter 2023 earnings released: EPS: ₩40.00 (vs ₩454 in 1Q 2022)First quarter 2023 results: EPS: ₩40.00 (down from ₩454 in 1Q 2022). Revenue: ₩5.73b (down 9.9% from 1Q 2022). Net income: ₩152.2m (down 91% from 1Q 2022). Profit margin: 2.7% (down from 27% in 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.
Valuation Update With 7 Day Price Move • May 11Investor sentiment improves as stock rises 30%After last week's 30% share price gain to ₩12,790, the stock trades at a trailing P/E ratio of 28.5x. Average trailing P/E is 25x in the Biotechs industry in South Korea. Total loss to shareholders of 7.6% over the past three years.
Upcoming Dividend • Dec 21Upcoming dividend of ₩75.00 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 19 April 2023. Trailing yield: 0.7%. Lower than top quartile of South Korean dividend payers (3.3%). In line with average of industry peers (0.7%).
Valuation Update With 7 Day Price Move • Sep 28Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩10,000, the stock trades at a trailing P/E ratio of 17.5x. Average trailing P/E is 21x in the Biotechs industry in South Korea. Total loss to shareholders of 44% over the past three years.
Valuation Update With 7 Day Price Move • Jun 20Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to ₩11,850, the stock trades at a trailing P/E ratio of 17.5x. Average trailing P/E is 23x in the Biotechs industry in South Korea. Total loss to shareholders of 36% over the past three years.
Reported Earnings • May 18First quarter 2022 earnings released: EPS: ₩454 (vs ₩6.00 in 1Q 2021)First quarter 2022 results: EPS: ₩454 (up from ₩6.00 in 1Q 2021). Revenue: ₩6.36b (up 14% from 1Q 2021). Net income: ₩1.73b (up ₩1.70b from 1Q 2021). Profit margin: 27% (up from 0.5% in 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.
Upcoming Dividend • Dec 22Inaugural dividend of ₩85.00 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 18 April 2022. The company is not currently making a profit and is not cash flow positive. This is the first dividend for Daesung Microbiological Labs since going public. The average dividend yield among industry peers is 0.8%.
Reported Earnings • May 19First quarter 2021 earnings released: EPS ₩6.00 (vs ₩204 in 1Q 2020)The company reported a poor first quarter result with weaker earnings, revenues and profit margins. First quarter 2021 results: Revenue: ₩5.60b (down 18% from 1Q 2020). Net income: ₩25.7m (down 97% from 1Q 2020). Profit margin: 0.5% (down from 12% in 1Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.
分析記事 • May 08Is Daesung Microbiological Labs (KOSDAQ:036480) Using Too Much Debt?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
分析記事 • Mar 15Is The Market Rewarding Daesung Microbiological Labs. Co., Ltd. (KOSDAQ:036480) With A Negative Sentiment As A Result Of Its Mixed Fundamentals?Daesung Microbiological Labs (KOSDAQ:036480) has had a rough month with its share price down 9.5%. We, however decided...
お知らせ • Feb 25Daesung Microbiological Labs. Co., Ltd., Annual General Meeting, Mar 26, 2021Daesung Microbiological Labs. Co., Ltd., Annual General Meeting, Mar 26, 2021, at 09:00 Korea Standard Time.
分析記事 • Feb 17We're Not Counting On Daesung Microbiological Labs (KOSDAQ:036480) To Sustain Its Statutory ProfitabilityIt might be old fashioned, but we really like to invest in companies that make a profit, each and every year. That...
分析記事 • Jan 21Is Daesung Microbiological Labs (KOSDAQ:036480) A Risky Investment?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Valuation Update With 7 Day Price Move • Jan 19Investor sentiment improved over the past weekAfter last week's 19% share price gain to ₩21,600, the stock is trading at a trailing P/E ratio of 33.7x, up from the previous P/E ratio of 28.3x. This compares to an average P/E of 62x in the Biotechs industry in South Korea. Total returns to shareholders over the past three years are 102%.
Valuation Update With 7 Day Price Move • Jan 13Investor sentiment improved over the past weekAfter last week's 30% share price gain to ₩21,700, the stock is trading at a trailing P/E ratio of 33.8x, up from the previous P/E ratio of 26x. This compares to an average P/E of 57x in the Biotechs industry in South Korea. Total returns to shareholders over the past three years are 111%.
Valuation Update With 7 Day Price Move • Jan 11Investor sentiment improved over the past weekAfter last week's 26% share price gain to ₩20,600, the stock is trading at a trailing P/E ratio of 32.1x, up from the previous P/E ratio of 25.5x. This compares to an average P/E of 58x in the Biotechs industry in South Korea. Total returns to shareholders over the past three years are 102%.
Is New 90 Day High Low • Jan 11New 90-day high: ₩20,600The company is up 24% from its price of ₩16,600 on 13 October 2020. The South Korean market is up 29% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is up 20% over the same period.
分析記事 • Dec 31Update: Daesung Microbiological Labs (KOSDAQ:036480) Stock Gained 83% In The Last Five YearsGenerally speaking the aim of active stock picking is to find companies that provide returns that are superior to the...
Upcoming Dividend • Dec 22Upcoming Dividend of ₩85.00 Per ShareWill be paid on the 17th of April to those who are registered shareholders by the 29th of December. The company last paid an ordinary dividend in March 2010. The average dividend yield among industry peers is 0.3%.
分析記事 • Dec 10Daesung Microbiological Labs. Co., Ltd. (KOSDAQ:036480) Is Up But Financials Look Inconsistent: Which Way Is The Stock Headed?Daesung Microbiological Labs' (KOSDAQ:036480) stock is up by 4.3% over the past month. However, the company's...
分析記事 • Nov 19Here's Why We Don't Think Daesung Microbiological Labs's (KOSDAQ:036480) Statutory Earnings Reflect Its Underlying Earnings PotentialStatistically speaking, it is less risky to invest in profitable companies than in unprofitable ones. However...